ImmunityBio (IBRX) Equity Income (2021 - 2023)
ImmunityBio (IBRX) posted quarterly Equity Income of -$442000.0 for Q2 2021, down 163.87% year-over-year from $692000.0 in Q2 2020, and down 163.87% quarter-over-quarter from $692000.0 in Q2 2020.
Powered by 
Analysis
ImmunityBio (IBRX) Equity Income (2021 - 2023) Analysis & Trends
ImmunityBio (IBRX) has reported Equity Income for 2 consecutive years, with -$442000.0 the latest figure, recorded in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 4.08 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 8.52 Bn | 8.16 Bn | 50.94 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -1.26 Mn |
| Jun 30, 2023 | -3.96 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.55 Mn |
| Sep 30, 2022 | -4.46 Mn |
| Jun 30, 2022 | -3.90 Mn |
| Mar 31, 2022 | -197,000.00 |
| Dec 31, 2021 | -803,000.00 |